Medicine Meda Pharmaceutical Information Consultancy

Meda is a leading international specialty pharmaceutical company that was acquired by Mylan in 2016 and is now a part of Viatris. The company's product portfolio is concentrated in several key therapeutic areas, including respiratory, dermatology, and pain and inflammation. Its flagship product, Dymista, is a widely used treatment for allergic rhinitis. The entity "Medicine Meda Pharmaceutical Information Consultancy" specifically refers to the company's operations in China, where it provides medical information and consultancy services to support its regional market presence. Following the merger of Mylan and Upjohn, Meda's assets and operations are fully integrated into the Viatris global healthcare network.